Q4 2023 Revance Therapeutics Inc Earnings Call Transcript
Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 financial results and corporate update conference call. (Operator Instructions) As a reminder, this call is being recorded on Wednesday, February 28, 2024. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Corporate Communications and ESG for events. Please go ahead.
Thank you, operator. Joining us on the call today from Revance, our Chief Executive Officer, Mark Foley, and Chief Financial Officer, Toby Schilke. During this call, management will make forward-looking statements, including statements related to the impact of our pricing and strategy OnDeck's focus on adoption expectations and timing related to product adoption and reorders of pop product pipeline, consumer needs, preferences and behavior, the benefits and value to US practices and consumers of our products, including the efficacy, duration and safety of our products, 2024 guidance, cash flow breakeven,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |